4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. It focuses on the research of MicroRx, its proprietary platform for the discovery of novel live bio therapeutics and the development of its pipeline. The company was founded on January 10, 2014 and is headquartered in Leeds, the United Kingdom.
Company profile
Ticker
LBPSW
Exchange
Website
CEO
Duncan Peyton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LBPSW stock data
Latest filings (excl ownership)
6-K
Notice of Cancellation of Admission to Trading on Aim
23 Feb 23
6-K
Current report (foreign)
17 Feb 23
6-K
Current report (foreign)
7 Feb 23
6-K
4D pharma Announces an Update on Administration and Suspension of Trading
3 Jan 23
6-K
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
18 Nov 22
6-K
Current report (foreign)
15 Nov 22
6-K
Current report (foreign)
7 Oct 22
6-K
Delay to publication of Interim Results
30 Sep 22
6-K
Current report (foreign)
24 Aug 22
6-K
Delisting of Securities of 4D pharma plc from The Nasdaq Stock Market
24 Aug 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2022
11.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 7 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 94.87 mm |
Total shares | 21.06 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MRK Merck & Co. | 12.15 mm | $66.19 mm |
Oliveira Steven Michael | 8.91 mm | $28.68 mm |
Tower Research Capital | 4.64 k | $0.00 |